مورد إلكتروني
Symposium Immunotherapy Trials in CAA and AD: The ARIA paradox in AD and CAA: merely an adverse event or an out of tune proof of immunotherapy effectiveness?
| العنوان: | Symposium Immunotherapy Trials in CAA and AD: The ARIA paradox in AD and CAA: merely an adverse event or an out of tune proof of immunotherapy effectiveness? |
|---|---|
| بيانات النشر: | 2016 |
| تفاصيل مُضافة: | Piazza, F PIAZZA, FABRIZIO |
| نوع الوثيقة: | Electronic Resource |
| مستخلص: | After a long history of failed clinical trials, we are currently experiencing an enthusiastic era for the treatment of amyloid-related neurodegenerative diseases. Phase1b data of aducanumab, a fully human antibody against Abeta42, is giving great promises and it is now moving directly into Phase3 in prodromal AD. Ponezumab, an antibody against Abeta40, has recently entered in Phase2 for CAA. Although the differences in terms of naturally history of these diseases and of drug-target engagement, increasing data are demonstrating that CAA and AD share different similarities that can perhaps mutually influence the design, safety, biomarkers profile and final outcomes interpretation of clinical trials |
| مصطلحات الفهرس: | Alzheimer's disease, Cerebral Amyloid Angiopathy, immunotherapy, clinical trials, biomarkers, MED/50 - SCIENZE TECNICHE MEDICHE APPLICATE, BIO/12 - BIOCHIMICA CLINICA E BIOLOGIA MOLECOLARE CLINICA, MED/04 - PATOLOGIA GENERALE, MED/05 - PATOLOGIA CLINICA, BIO/14 - FARMACOLOGIA, info:eu-repo/semantics/conferenceObject |
| URL: | ispartofbook:International CAA Conference September 8-10 2016 Boston MA International CAA Conference September 8-10 |
| الإتاحة: | Open access content. Open access content |
| ملاحظة: | STAMPA English |
| أرقام أخرى: | ITBAO oai:boa.unimib.it:10281/107018 1311392566 |
| المصدر المساهم: | BICOCCA OPEN ARCH From OAIster®, provided by the OCLC Cooperative. |
| رقم الأكسشن: | edsoai.on1311392566 |
| قاعدة البيانات: | OAIster |
| الوصف غير متاح. |